Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis
- 17 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Clinical Immunology
- Vol. 31 (6), 1010-1020
- https://doi.org/10.1007/s10875-011-9579-6
Abstract
Multiple sclerosis is an autoimmune disease of the central nervous system characterized by neuroinflammation and demyelination. Although considered a T cell-mediated disease, multiple sclerosis involves the activation of both adaptive and innate immune cells, as well as resident cells of the central nervous system, which synergize in inducing inflammation and thereby demyelination. Differentiation, survival, and inflammatory functions of innate immune cells and of astrocytes of the central nervous system are regulated by tyrosine kinases. Here, we show that imatinib, sorafenib, and GW2580—small molecule tyrosine kinase inhibitors—can each prevent the development of disease and treat established disease in a mouse model of multiple sclerosis. In vitro, imatinib and sorafenib inhibited astrocyte proliferation mediated by the tyrosine kinase platelet-derived growth factor receptor (PDGFR), whereas GW2580 and sorafenib inhibited macrophage tumor necrosis factor (TNF) production mediated by the tyrosine kinases c-Fms and PDGFR, respectively. In vivo, amelioration of disease by GW2580 was associated with a reduction in the proportion of macrophages and T cells in the CNS infiltrate, as well as a reduction in the levels of circulating TNF. Our findings suggest that GW2580 and the FDA-approved drugs imatinib and sorafenib have potential as novel therapeutics for the treatment of autoimmune demyelinating disease.Keywords
This publication has 68 references indexed in Scilit:
- An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammationBlood, 2010
- c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritisArthritis Research & Therapy, 2010
- Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences of the United States of America, 2008
- T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosisImmunology, 2008
- Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitisBMC Immunology, 2007
- Active induction of experimental allergic encephalomyelitisNature Protocols, 2006
- Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritisJCI Insight, 2006
- Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cellsCytometry Part B: Clinical Cytometry, 2006
- ORGANOTINS DISRUPT COMPONENTS OF GLUTAMATE HOMEOSTASIS IN RAT ASTROCYTE CULTURESJournal of Toxicology and Environmental Health, Part A, 2001
- Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages.The Journal of Experimental Medicine, 1990